Intrinsically disordered proteins (IDPs) do not attain a stable secondary or tertiary structure and rapidly change their ...

TEDC1 and TEDC2, functions in generating centriolar triplet microtubules, and that this is crucial for the proper formation of centriolar subdomains and the stability of centrioles throughout the cell ...

Researchers found that TEX38 and ZDHHC19 co-localize on the plasma membrane of spermatids and mediate S-palmitoylation of ARRDC5, a crucial protein for spermatogenesis. Disrupting either TEX38 or ...

capsid (protein shell) and a high-activity human coagulation FIX gene. The purpose of this gene therapy is for those people living with haemophilia B, once treated, to be able to produce FIX via ...

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia. The recommendation by the EMA's ...

Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU that can be delivered via an autoinjector device at home.

Researchers from The University of Texas at Arlington and the University of California–San Francisco have used a new ...

There has been a gene therapy on the market for people with the bleeding disorder haemophilia A since 2022, but take-up has been very slow. Pfizer and Sangamo are hoping for a faster trajectory ...

The approval keeps uniQure in pole position over its closest rival in the haemophilia B gene therapy race, Pfizer/Roche, whose fidanacogene elaparvovec candidate is in the BENEGENE-2 trial, due to ...